Due to the inherent heterogeneity of GBM, molecular targeted therapy including inhibitors of EGFRvIII (3), phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) (NCT00595954), and mammalian target of rapamycin (mTOR)(NCT00515086 and NCT00016328) have failed to produce any survival benefit over standard treatment (4). This evidence concerns the gene MTOR and glioblastoma.